Besifovir dipivoxil maleate


150 mg PO once daily + L-carnitine 660 mg

Safety and efficacy in pediatric patients <18y of age have not been established

Compensated cirrhosis No dose adjustment

Decompensated cirrhosis No data

Mild renal impairment Use with caution

Moderate to severe renal impairment No data

General Information

Type B viral hepatitis, chronic

Monitor liver and renal function.

Monitor serum L-carnitine levels.

Test for HIV antibodies prior to treatment.

  • Nasopharyngitis

  • Indigestion

  • Fatigue

  • Headache

  • Increased liver enzymes

  • Lumbago

  • Skin reactions (e.g. hives, rash, dermatitis)

  • Malignant or unspecified neoplasm

Drugs that reduce renal function or compete for active tubular secretion

Antimicrobial class: Antiviral agent

Average serum half life: 2-3 hours (Besifovir), 45-90 hours (LB80317)

Precautions: Severe acute exacerbations of HBV have been reported in patients who discontinued anti-hepatitis B therapy; monitoring recommended with clinical and laboratory follow-up.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.